'Pay for Delay' Pharma Deals Get Once-Over From Supreme Court
WASHINGTON The U.S. Supreme Court on Monday searched for middle ground in the ongoing antitrust battle between the Federal Trade Commission and the pharmaceutical industry over patent settlements in which brand-name manufacturers pay generic drug companies to delay entering the market.
This content has been archived. It is available exclusively through our partner LexisNexis®.
To view this content, please continue to Lexis Advance®.
Not a Lexis Advance® Subscriber? Subscribe Now
For questions call 1-877-256-2472 or contact us at email@example.com